Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
Portfolio Pulse from
SOPHiA GENETICS has announced significant global adoption of its cancer testing applications, MSK-ACCESS® and MSK-IMPACT®, powered by SOPHiA DDM™. Thirty-seven leading institutions have adopted these applications for liquid biopsy and solid tumor testing.
February 24, 2025 | 9:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SOPHiA GENETICS has achieved a milestone with 37 institutions adopting its MSK-ACCESS® and MSK-IMPACT® applications, indicating strong market acceptance and potential revenue growth.
The adoption of SOPHiA GENETICS' applications by 37 institutions suggests strong market acceptance and potential for increased revenue. This is a positive development for the company, likely to boost investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100